Alpha Paradigm Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Alpha Paradigm Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,413	Closed	-$973K	–	590
2022 Q3	$973K	Buy	1,413 +1,271	+895%	+$800K	0.42%	67
2022 Q2	$84K	Buy	+142	New	+$92.3K	0.03%	410
2022 Q1	–	Sell	-989	Closed	-$625K	–	662
2021 Q4	$625K	Buy	989 +221	+29%	+$136K	0.25%	121
2021 Q3	$465K	Sell	768 -2,718	-78%	-$1.69M	0.19%	189
2021 Q2	$1.95M	Buy	+3,486	New	+$1.77M	0.73%	16

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Alpha Paradigm Partners's REGN Position: Q4 2022 in Review

Alpha Paradigm Partners sold out of Regeneron Pharmaceuticals (REGN) in Q4 2022, closing a stake of 1,413 shares — an estimated $973K sold.

Alpha Paradigm Partners first reported a position in REGN in Q2 2021 and held it in 5 quarters. The position peaked at $1.95M in Q2 2021. 1,158 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

Alpha Paradigm Partners reported no remaining Regeneron Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Alpha Paradigm Partners sold 1,413 Regeneron Pharmaceuticals shares in Q4 2022, an estimated $973K.
Alpha Paradigm Partners first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 5 quarters.
Alpha Paradigm Partners's Regeneron Pharmaceuticals position peaked at $1.95M in Q2 2021.
1,158 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on Alpha Paradigm Partners's 13F filing for Q4 2022, filed 13 Feb 2023.